JAK2 and atherosclerosis: Given the pivotal role of this phenotypic switch in the pathogenesis of atherosclerosis, it is crucial to identify effective therapeutic agents that target the JAK2/STAT3/KLF4 pathway to inhibit the transition of VSMCs to macrophage-like cells.